nDatalyze Corp. Announces Adoption of Semi-Annual Financial Reporting Trial, provides a progress report on the potential RTO, and updates the Epitome sports performance assessment project

Executive Summary

• nDatalyze Corp. will adopt the Canadian Securities Administrators’ Semi‑Annual Reporting (SAR) Pilot, moving from quarterly to semi‑annual financial reporting to reduce administrative burden.
• The company received confirmation that its pre‑RTO financing with Prism Diversified Ltd. is proceeding, positioning it to execute a definitive RTO agreement soon.
• Completion of the Epitome sports performance assessment commercialization report provides clear market prioritization and pricing strategy for upcoming product rollout.

Key Details

• SAR Pilot Adoption:
• Fiscal year ends Feb 28; first‑quarter interim report (Q1 ending May 31, 2026) will not be filed.
• Audited annual financial statements remain due within 120 days of fiscal year‑end; six‑month interim reports due within 60 days of Aug 31.

• Company remains subject to NI 51‑102 continuous disclosure obligations for material changes.

• Eligibility Confirmation:

• Venture issuer with annual revenues < $10 M and a clean 12‑month continuous disclosure record meets SAR Pilot criteria.

• RTO Update – Prism Diversified Ltd.:

• Pre‑RTO financing is underway; company expects to sign a definitive RTO agreement in the near term.

• Management expresses confidence that the RTO will be completed as planned.

• Epitome Sports Performance Assessment Project:

• Commercialization report finalized after input from ALPS Hockey Academy (Italy), MacLauchlan College (Canada) and Okanagan Hockey (Canada).
• Report defines priority target markets, optimal buyer personas (scout, coach, JV partner), pricing structure, and seasonal sales cycle.
• Company is evaluating commercialization pathways and will provide updates as decisions are made.

Notable Quotes

• “By adopting the SAR Pilot we can focus more resources on our core technology‑driven mental health solutions while still meeting our disclosure obligations,” – Jim Durward, President & CEO/CTO.
• “The feedback from leading hockey academies gives us confidence in the market positioning and pricing strategy for Epitome,” – Jim Durward.